glp-1 kidney protection agonists in the treatment of chronic disease in type 2 diabetes and obesity GLP-1 Receptor Agonists and Kidney
Description
Semaglutide was the first to break through
Weight management can vary depending on various factors, such as starting weight, body type, and lifestyle
Eur J Pharmacol (2022) 926:175029
The Ozempic response was filed with the Panel on December 29, 2023
However, measurable weight loss on the scale typically becomes apparent after 46 weeks of treatment
Protein intake becomes especially important on GLP-1 therapy because significant weight loss can include lean muscle mass if protein intake is inadequate
